American Neurological Association

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Discovery of Genetic Link to PML Honored by Largest MS Conference in the World

Retrieved on: 
Tuesday, October 17, 2023
Emerald, Dimethyl fumarate, DRS, Best, FAERS, Great America Committee, Cladribine, MS, Research, JC, Abstract, Brain, Biogen, Breast cancer, COVID, Multiple myeloma, Treatment, Daratumumab, Risk, CLIA, Natalizumab, Multiple sclerosis, Discovery, Belimumab, Death, Health, PML, Disease, American Neurological Association, Rheumatoid arthritis, FDA, Database, Gene, Human polyomavirus 2, BRCA, Bone marrow, Black box, Inflammatory bowel disease, Infection, PPV, Ibrutinib, Rituximab, Lupus, Progressive multifocal leukoencephalopathy, HIV/AIDS, Patient, Pharmaceutical industry

NEWPORT BEACH, Calif., Oct. 17, 2023 /PRNewswire/ -- The discovery of rare genomic variants leading to cases of drug-induced PML shared Best of MSMilan2023 honors for the latest and most breakthrough results at the 9th Joint ECTRIMS-ACTRIMS Meeting.

Key Points: 
  • Two of the variants have a Positive Predictive Value of 100%, the strongest possible indication they are causative.
  • Progressive Multifocal Leukoencephalopathy (PML) is a rare but frequently fatal serious infection of the brain by the JC virus.
  • Out of 1,500 abstracts presented, Dr. Hatchwell's was one of eight highlighted as Best of MSMilan2023 in its content area.
  • Many MS medications currently carry a PML warning, including Tysabri, Ocrevus, and Rituxan, as well as Briumvi, Gilenya, Kesimpta, Mavenclad, Mayzent, Ponvory, and Tecfidera.

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Retrieved on: 
Monday, September 11, 2023
PD, American Neurological Association, Half-life, IGNITE, Pharmacokinetics, SAD, Biomarker, Publication, MRI, Data analysis, Magnetic resonance imaging, TREM2, Data, Patient, ANA, MAD, Microglia, CSF, CSF1R, Safety, Pharmaceutical industry, Generic drug, Medical imaging, ALSP

WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the complete data analysis from its VGL101 Phase 1 single and multiple ascending dose (SAD and MAD) healthy volunteer trial in a poster presentation at the 2023 American Neurological Association (ANA) Annual Meeting. In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.

Key Points: 
  • In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.
  • “The dataset from the VGL101 Phase 1 healthy volunteer trial is very encouraging and further validates our development strategy for the ongoing IGNITE Phase 2 trial in ALSP.
  • “We are committed to achieving further milestones for VGL101, including the interim data readout from IGNITE in the fourth quarter of 2023.
  • In a separate poster at the ANA Annual Meeting, the Company presented the trial design for its ongoing Phase 2 IGNITE trial.

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

Retrieved on: 
Monday, September 11, 2023
Cognition, Insulin resistance, WHR, DNA, Hyperglycemia, Dyslipidemia, Methylation, Hypertriglyceridemia, American Neurological Association, Calendar, Deficit spending, Risk, Inflammation, Biomarker, MCI, Hypertension, Hypercholesterolemia, CDR, RANTES, AAIC, Dementia, HIV disease progression rates, ANA, CRP, Complement component 1q, Patient, Probability, Abdominal obesity, Poster, CSF, ADAS, DNA methylation, AD, Gene, APOE, MMSE, Conference, Pharmaceutical industry, Nursing

CARSON CITY, Nev., Sept. 11, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that preliminary baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD) was presented as a poster at the American Neurological Association (ANA) annual meeting, being held September 11-13, 2023 in Philadelphia, PA.

Key Points: 
  • The poster, Metabolic Dysregulation in Probable Alzheimer’s Disease (Christopher Reading, et al), is being presented by Joseph Palumbo, Chief Medical Officer of BioVie, and highlights the preliminary baseline metabolic and inflammation characteristics from the Phase 3 study population (see Table 1).
  • “Instead, it provides an understanding of the patient population at the start of the trial, as understood to date.
  • At baseline, the majority of the study population are coded with abdominal obesity (85%), hypertension (61%), and impaired glucose metabolism (IFG/T2D; 52%).
  • Both Aβ+ and Aβ− patients with dementia were enrolled in the study and had, at baseline, comparable CDR-SB scores indicative of mild dementia.

NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association

Retrieved on: 
Friday, September 8, 2023
Nextgen, University, Q&A, American Neurological Association, EVP, Myasthenia gravis, Neuromuscular junction, MG, Patient, Physician, MD, NMJ, Entrepreneurship, Poster, Phase, Pharmaceutical industry

The 148 th Annual Meeting of the American Neurological Association is taking place from 9-12 September, Philadelphia, US.

Key Points: 
  • The 148 th Annual Meeting of the American Neurological Association is taking place from 9-12 September, Philadelphia, US.
  • It is designed to provide expert insight into the treatment landscape for patients and to explore likely developments in treatment over the coming years.
  • NMD Pharma will be also presenting new clinical data from the Phase I/IIa trial of NMD670 in patients with MG in a poster presentation at the conference, which follows the announcement of positive topline data from the trial in October 2022.
  • Jorge A. Quiroz MD, EVP, Chief Medical Officer at NMD Pharma commented, “I look forward to attending the ANA Annual Meeting and sharing our new data from our lead clinical development program in myasthenia gravis.

Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Oncology, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, POC, Senior, American Neurological Association, CC, Muscular dystrophy, PET, IL-6, Brain, Research, Houston Methodist Hospital, Dementia, CCL4, COYA, Cerebral cortex, Regulatory T cell, Biology, AAIC, Uneme language, HIV disease progression rates, Patient, Master of Science, Blood, Regulatory affairs, Regulation, Next Generation, AD, FDA, Therapy, R, Positron emission tomography, IND, MMSE, Conference, Interleukin, Safety, Neuroinflammation, Pharmaceutical industry, Cryptocurrency, ALS, MD

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update.
  • Study data were presented at the 2023 Keystone Symposia Neurodegeneration: Biology Guiding the Next Generation of Therapeutic Development.
  • COYA 301 is Coya’s proprietary ld IL-2 formulation that is intended to enhance anti-inflammatory regulatory T cell function and numbers.
  • The Company expects general and administrative costs to continue to grow in 2023 as Coya expands its business development activities as well as incur additional public company costs.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Retrieved on: 
Thursday, June 22, 2023
Research, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Therapy, Lancet Neurology, Phase II, Neurotoxicity, Efficacy, Immunoglobulin therapy, Clinical trial, Bone marrow, Oregon Health & Science University, NIH, Chapel Hill, DRS, University of South Florida, Myasthenia gravis, RNA, Autoimmunity, University of Miami, Bangladesh Technical Education Board, CAR, DSM-IV codes, National Institute of Neurological Disorders and Stroke, Cytokine release syndrome, MG, Patient, Physician, Northwestern Health Sciences University, Autotransplantation, NINDS, Paper, Toxic encephalopathy, American Neurological Association, Immunosuppression, Myasthenia, The Lancet, Lancet, Safety, Pharmaceutical industry, Vaccine, Stroke, Cartesian

Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Key Points: 
  • Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
  • The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease.
  • This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.
  • Clinical benefit was sustained long-term for most patients, even months after completing the course of therapy.

NYU LANGONE HEALTH EXPANDS ACCESS TO TOP-RANKED NEUROLOGY PROGRAM IN SUFFOLK COUNTY

Retrieved on: 
Monday, May 1, 2023
NYU Langone Health, Ambulatory care, NYU, American Neurological Association, Neurology, Patient, Nursing

NEW YORK, May 1, 2023 /PRNewswire/ -- NYU Langone Health and South Shore Neurologic Associates today join forces, enhancing access to high-quality specialized care in Suffolk County with three NYU Langone South Shore Neurologic Associates locations in Patchogue, Riverhead, and Islip.

Key Points: 
  • NEW YORK, May 1, 2023 /PRNewswire/ -- NYU Langone Health and South Shore Neurologic Associates today join forces, enhancing access to high-quality specialized care in Suffolk County with three NYU Langone South Shore Neurologic Associates locations in Patchogue , Riverhead , and Islip .
  • 1 ranked neurology and neurosurgery program in the nation," said Andrew Rubin, senior vice president for clinical affairs and ambulatory care at NYU Langone.
  • A single electronic health record system, the NYU Langone Health app , and NYU Langone Health MyChart connect the entire health system, so patients can find all of their health information in one place.
  • Specialists at NYU Langone South Shore Neurologic Associates offer a wide range of neurology care across three sites, including:

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023
Patent, REMS, FDA Adverse Event Reporting System, United States Court of Appeals for the Federal Circuit, Cataplexy, American Neurological Association, Marketing, EDS, Narcolepsy, Federal district, Orange Book, District court, ANA, Patient, United States courts of appeals, Risk, RTW, American College of Chest Physicians, Webcast, Jazz Pharmaceuticals, Growth, American College, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Douglas v. U.S. District Court ex rel Talk America, Food, Generic drug, Pharmaceutical industry, Cryptocurrency, Music, Avadel Pharmaceuticals, FAERS

ET

Key Points: 
  • ET
    DUBLIN, Ireland, March 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2022.
  • Collectively, these milestones move us closer to the potential commercialization of LUMRYZ,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals.
  • I want to thank all stakeholders including patients, healthcare practitioners, and our investors for their strong support during this process.
  • Avadel will host a conference all and live audio webcast to discuss its fourth quarter and full year quarter 2022 financial results and provide a corporate update today at 8:30 a.m.

Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses

Retrieved on: 
Wednesday, January 25, 2023
Machine learning, Capital Group Companies, American Neurological Association, Precision, Stroke, Electrode, Capital, Traumatic brain injury, Microelectrode, Tim Draper, FDA, Dementia, Migraine, Hair, Brain, BCI, Medical device, Scotch

The latest investment brings the company’s total funding to $53 million in under two years.

Key Points: 
  • The latest investment brings the company’s total funding to $53 million in under two years.
  • “We imagine a world where devastating neurological conditions – stroke, traumatic brain injury, dementia – are finally treatable,” Michael Mager, CEO of Precision Neuroscience, said.
  • Precision is excited to take on that challenge.”
    According to the American Neurological Association, nearly 100 million people in the U.S. alone suffer from neurological conditions ranging from migraines to Parkinson’s disease.
  • “Precision is pioneering a BCI product that we believe will achieve patient outcomes that were previously thought to be impossible.”